Paid and unpaid productivity losses due to premature mortality from cancer in Europe in 2018.
Europe
cancer
human capital approach
mortality
productivity lost
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 02 2022
15 02 2022
Historique:
revised:
15
08
2021
received:
22
02
2021
accepted:
06
09
2021
pubmed:
28
9
2021
medline:
19
2
2022
entrez:
27
9
2021
Statut:
ppublish
Résumé
When someone dies prematurely from cancer this represents a loss of productivity for society. This loss can be valued and provides a measure of the cancer burden. We estimated paid and unpaid productivity lost due to cancer-related premature mortality in 31 European countries in 2018. Lost productivity was estimated for all cancers combined and 23 cancer sites, overall, by region and country. Deaths aged 15 to 64 were abstracted from GLOBOCAN 2018. Unpaid time lost (housework, caring, volunteering) was derived from Eurostat. Paid and unpaid productivity losses were valued using the human capital approach. In total, 347,149 premature cancer deaths occurred (60% male). The total value of cancer-related lost productivity was €104.6 billion. Of this, €52.9 billion (50.6%) was due to lost paid work, and €51.7 billion (49.4%) to unpaid work. Females accounted for 36.7% of paid work costs but half (51.1%) of the unpaid work costs. Costs were highest in Western Europe (€52.0 billion). The most costly cancer was lung (€21.7 billion), followed by breast (€10.6 billion). The average loss per premature death was highest for Hodgkin's lymphoma (€506 345), melanoma (€450 694), brain cancer (€428 449) and leukaemia (€378 750). Cancer-related lost productivity costs are significant. Almost half are due to unpaid work losses, indicating the importance of considering both paid and unpaid labour in assessing the cancer economic burden. The high cost per premature death of some less common cancers illustrates the potential benefits that could accrue from investment in prevention and control of these cancers.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
580-593Informations de copyright
© 2021 UICC.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Grossman M. On the concept of health capital and the demand for health. J Polit Econ. 1972;80:223-255.
Oliva J, Rodríguez-Sánchez B, Peña-Longobardo LM, Aranda-Reneo I & López-Bastida J. Impact HTA: revising the methodological aspects applied to the identification, measurement and valuation of social costs in economic evaluations. https://wwwimpact-htaeu/work-package-4. Accessed January 2021.
Hanly P, Sharp L. The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer. 2014;14:224-233.
Hao S, Östensson E, Eklund M, et al. The economic burden of prostate cancer-a Swedish prevalence-based register study. BMC Health Serv Res. 2020;20:448.
Darbà J, Marsà A. The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period. BMC Cancer. 2019;19:992.
Łyszczarz B, Nojszewska E. Productivity losses and public finance burden attributable to breast cancer in Poland, 2010-2014. BMC Cancer. 2017;17:676.
Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol. 2016;69:438-447.
Pearce A, Bradley C, Hanly P, et al. Projecting productivity losses for cancer-related mortality 2011-2030. BMC Cancer. 2016;16(1):804.
Ortega-Ortega M, Oliva-Moreno J, Jimenez-Aguilera Jde D, Romero-Aguilar A, Espigado-Tocino I. Productivity loss due to premature mortality caused by blood cancer: a study based on patients undergoing stem cell transplantation. Gac Sanit. 2015;29:178-183.
Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015;136:E136-E145.
Hofmarcher T, Lindgren P, Wilking N, Jönsson B. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41-49.
Łyszczarz B. Production losses associated with premature mortality in 28 European Union countries. J Glob Health. 2019;9:020418.
Jönsson B, Hofmarcher T, Lindgren P, Wilking N. The cost and burden of cancer in the European Union 1995-2014. Eur J Cancer. 2016;66:162-170.
Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165-1174.
Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML. Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst. 2008;100:1763-1770.
United Nations Development Programme, Human development report 2020: the next frontier, human development and the anthropocene, New York, United States of America: United Nations Publications; 2020.
International Agency for Research on Cancer. Cancer Today. https://gco.iarc.fr/today/home. Accessed January 2021.
World Health Organisation. WHO methods and data sources for global burden of disease estimates 2000-2015. https://www.who.int/healthinfo/global_burden_disease/GlobalDALYmethods_2000_2015.pdf. Accessed January 2021.
Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32:335-344.
Eurostat. GDP and main components (output, expenditure and income). Current prices. 2018. https://ec.europa.eu/eurostat/web/national-accounts/data/database. Accessed January 2021.
Massetti M, Aballéa S, Videau Y, Rémuzat C, Roïz J, Toumi M. A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments. J Mark Access Health Policy. 2015;3:24966.
Eurostat. Mean annual earnings by sex, age and occupation. 10 employees or more. 2014. https://ec.europa.eu/eurostat/web/labour-market/earnings/database. Accessed January 2021.
Eurostat. Harmonized index of consumer price-inflation rate. Annual average rate of change. 2019. https://ec.europa.eu/eurostat/databrowser/product/page/TEC00118. Accessed January 2021.
Eurostat. Unemployment rates by sex, age and country of birth (%). 2018. https://ec.europa.eu/eurostat/web/lfs/data/database. Accessed January 2021.
International Labour Organization (ILOSTAT). Labour force participation rate by sex and age. Percentage of total population. https://ilostat.ilo.org/data/. Accessed January 2021.
Eurostat. Time use survey. Population and social condition. 2010. https://ec.europa.eu/eurostat/databrowser/view/tus_00age/default/table?lang=en. Accessed January 2021.
Organisation for Economic Cooperation and Development (OECD). Social protection and well-being database. Time survey. https://stats.oecd.org/Indexaspx?DataSetCode=TIME_USE. Accessed January 2021.
Van den Berg B, Brouwer WB, Koopmanschap MA. Economic valuation of informal care. Eur J Health Econ. 2004;5:36-45.
Van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GA, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62:835-845.
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023-1075.
Bertuccio P, Alicandro G, Malvezzi M, et al. Cancer mortality in Europe in 2015 and an overview of trends since 1990. Ann Oncol. 2019;30:1356-1369.
Carioli G, Bertuccio P, Boffetta P, et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol. 2020;31:650-658.
Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur J Cancer Prev. 2015;24:141-149.
Penfold C, Joannides AJ, Bell J, Walter FM. Diagnosing adult primary brain tumours: can we do better? Br J Gen Pract. 2017;67:278-279.
Walter FM, Penfold C, Joannides A, et al. Missed opportunities for diagnosing brain tumours in primary care: a qualitative study of patient experiences. Br J Gen Pract. 2019;69:e224-e235.
Eurostat. Healthcare activities statistics-preventive services. https://ec.europa.eu/eurostat/statistics-explained/index.php/Healthcare_activities_statistics_-_preventive_services#Cervical_cancer_screening. Accessed January 2021.
Gianino MM, Lenzi J, Bonaudo M, et al. Organized screening programmes for breast and cervical cancer in 17 EU countries: trajectories of attendance rates. BMC Public Health. 2018;18:1236.
López N, Garcés-Sánchez M, Panizo MB, et al. HPV knowledge and vaccine acceptance among European adolescents and their parents: a systematic literature review. Public Health Rev. 2020;41:10.
Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013;31:537-549.
Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16:765-778.
European Commission 2018 Ageing report economic & budgetary projections for the 28 EU Member States (2016-2070). Publications of the European Union Institutional Paper 079. https://ec.europa.eu/info/sites/info/files/economy-finance/ip079_en.pdf. Accessed January 2021.
Pilleron S, Sarfati D, Janssen-Heijnen M, et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144:49-58.
Eurofound. https://www.eurofound.europa.eu/topic/retirement, vol. 2021, 2021.
Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20:1493-1505.
World Cancer Research Fund / American Institute for Cancer Research, Diet, nutrition, physical activity and cancer: a global perspective. Continuous Update Project Expert Report 2018. 2018. https://www.dietandcancerreport.org. Accessed January 2021.
U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50Years of Progress. A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
Gheorghe A, Maringe C, Spice J, et al. Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: a national population-based modelling study in England, UK. Eur J Cancer. 2021;152:233-242.
Van Mol P, Franken A, Dooms C, et al. LBA78 a microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden. Ann Oncol. 2020;31:S1207.
Hanly P, Ahern M, Sharp L, Ursul D, Loughnane G. The cost of lost productivity due to premature mortality associated with COVID-19: a pan-European study. Eur J Health Econ. 2021;21:1-11.
Koopmanschap MA, Rutten FF, van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171-189.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2015.